{"gene":"FCGR2B","run_date":"2026-06-09T23:54:43","timeline":{"discoveries":[{"year":1997,"finding":"SHP-1 is dispensable for FcγRIIB-mediated inhibition of B cell antigen receptor (sIgM) signaling; instead, SHIP (inositol 5'-phosphatase) is recruited to tyrosyl-phosphorylated FcγRIIB and mediates inhibition of calcium influx and CD19 dephosphorylation in B cells.","method":"Immortalized B cell lines from motheaten (SHP-1-deficient) mice and normal littermates; co-ligation of FcγRIIB and sIgM; calcium influx assays; co-immunoprecipitation of SHIP with FcγRIIB","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP and functional calcium assays in defined genetic KO cell lines; finding independently corroborated by parallel mast cell studies","pmids":["9242674"],"is_preprint":false},{"year":1999,"finding":"FcγRIIB co-ligation with the B cell antigen receptor suppresses Akt activation by reducing PIP3 accumulation via SHIP-mediated hydrolysis, despite normal PI3K activation; SHIP acts downstream of FcγRIIB to consume PIP3 and block Akt.","method":"A20 murine B cell line; sIg-FcγRIIB co-clustering; PIP3 measurement; Akt kinase assays; comparison with SHIP-deficient avian B cells and fibroblasts expressing catalytically active vs. inactive SHIP","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro enzymatic mechanism established with catalytic-dead SHIP mutant, SHIP-null cells, and direct PIP3 measurement; multiple orthogonal approaches in one study","pmids":["10224144"],"is_preprint":false},{"year":2002,"finding":"FcγRIIB negatively regulates mast cell proliferation when co-aggregated with Kit (SCF receptor): inhibits G1 entry, cyclins D2/D3/A induction, ERK/JNK/p38 activation, and Akt phosphorylation via SHIP recruitment; SHIP-null cells lose Akt and ERK inhibition but retain partial proliferation inhibition; a chimeric FcγRIIB bearing SHIP's catalytic domain mimics full inhibition.","method":"Mast cell co-aggregation assays; thymidine incorporation; cell cycle analysis; SHIP co-precipitation with FcγRIIB; SHIP-/- cells; chimeric receptor constructs","journal":"Molecular immunology","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods (KO cells, chimeric constructs, cell cycle, kinase assays) in one study; catalytic-domain replacement validates SHIP as key effector","pmids":["12217398"],"is_preprint":false},{"year":2002,"finding":"A 13-nt deletion polymorphism in the Fcgr2b promoter found in autoimmune-prone NZB mice abolishes AP-4 transcription factor binding, reducing FcγRIIB1 expression in germinal center B cells and increasing IgG antibody responses.","method":"Luciferase reporter assays; EMSA and Southwestern analysis for AP-4 binding; congenic C57BL/6 mice carrying NZB Fcgr2b allele","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — promoter-reporter assay with EMSA identification of AP-4 as the relevant transcription factor, complemented by in vivo congenic mouse data; single lab, two orthogonal methods","pmids":["12370366"],"is_preprint":false},{"year":2003,"finding":"The I232T (Ile187Thr in earlier numbering) transmembrane domain polymorphism of FcγRIIB alters receptor signaling: the 187T allele mediates greater CD19 dephosphorylation and stronger inhibition of BCR-induced calcium response than 187I, independently of the ITIM, when co-engaged with BCR; both alleles similarly modulate BCR-induced and anti-Fas-induced apoptosis.","method":"Expression of both allelic forms (full-length and ITIM-truncated) in FcγRIIB-negative IIA1.6 mouse B cell line; CD19 phosphorylation assays; calcium flux assays; apoptosis assays","journal":"Arthritis and rheumatism","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstitution in null cell line with truncated-domain constructs isolates transmembrane contribution; multiple functional assays; single lab","pmids":["14613290"],"is_preprint":false},{"year":2004,"finding":"A less-frequent FCGR2B promoter haplotype drives increased expression of FcγRIIB in luciferase reporter assays in both B lymphoid and myeloid cell lines under constitutive and stimulated conditions, and is associated with SLE susceptibility.","method":"Luciferase reporter assays; identification of 10 novel SNPs; case-control genetic study in 600 Caucasians","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional reporter assay establishes promoter activity difference; single lab, one functional method complemented by genetic association","pmids":["15153543"],"is_preprint":false},{"year":2005,"finding":"FcγRIIB mediates CRP inhibition of endothelial NO synthase (eNOS): CRP signals through FcγRIIB expressed in endothelium to activate PP2A, blunting eNOS phosphorylation at Ser1179 and impairing vasodilatation in vivo.","method":"Cultured endothelium; siRNA knockdown of PP2A; heterologous FcγRIIB expression; FcγRIIB+/+ vs FcγRIIB-/- mice with acetylcholine vascular conductance assays; aggregated IgG as FcγR ligand","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 / Strong — siRNA knockdown, heterologous expression, and in vivo KO mouse vascular function assays all converge on FcγRIIB–PP2A–eNOS mechanism; multiple orthogonal approaches","pmids":["16269657"],"is_preprint":false},{"year":2007,"finding":"FcγRIIB is expressed on bone marrow plasma cells; crosslinking FcγRIIB on plasma cells induces apoptosis, controlling their persistence in the bone marrow. Plasma cells from lupus-prone mice lack FcγRIIB expression and are protected from apoptosis. Human plasmablasts and FcγRIIB-expressing myeloma cells are also killed by FcγRIIB crosslinking.","method":"Flow cytometry of plasma cell FcγRIIB expression; crosslinking antibody-induced apoptosis assays; comparison between wild-type and lupus-prone mouse plasma cells; human plasmablast and myeloma cell assays","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct crosslinking functional assay in both mouse and human cells; in vivo genetic model; multiple cell types tested; replicated across species","pmids":["17322888"],"is_preprint":false},{"year":2008,"finding":"Cell-type-specific overexpression of FcγRIIB reveals distinct roles: B cell overexpression reduces IgG responses and ameliorates collagen-induced arthritis and SLE; macrophage overexpression has no effect on autoimmunity but increases mortality after S. pneumoniae infection.","method":"Transgenic mice overexpressing FcγRIIB under B cell- or macrophage-specific promoters; T-dependent immune response assays; collagen-induced arthritis model; S. pneumoniae infection model","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific transgenic dissection with multiple disease models; defines differential cell-autonomous roles; single lab, multiple orthogonal in vivo readouts","pmids":["18362174"],"is_preprint":false},{"year":2008,"finding":"FGL2 (fibrinogen-like protein 2) binds specifically to FcγRIIB and FcγRIII on APC surfaces; FcγRIIB binding mediates FGL2-induced inhibition of DC maturation and apoptosis of FcγRIIB+ B cells; FcγRIIB is required for FGL2's immunosuppressive and allograft-prolonging effects in vivo.","method":"Flow cytometry and surface plasmon resonance for FGL2–FcγRIIB binding; FcγRIIB-/- vs wild-type BMDC maturation assays; A20 vs A20IIA1.6 (FcγRIIB-negative) apoptosis assay; skin allograft survival in FcγRIIB+/+ vs FcγRIIB-/- mice","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — SPR establishes direct binding; multiple functional assays in null cell line and KO mice; two orthogonal binding methods plus in vivo validation","pmids":["18991288"],"is_preprint":false},{"year":2008,"finding":"FcγRIIB co-aggregation with BCR dampens BCR-induced BLyS receptor upregulation in a SHIP1-dependent manner, subsequently attenuating BLyS survival signals (Pim-2, non-canonical NF-κB, Bcl-xL) in B cells.","method":"B cell co-aggregation assays; BLyS receptor expression and signaling assays; SHIP1-deficient cells; pharmacological dissection","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional co-ligation assay with SHIP1-deficient comparison; single lab, two orthogonal downstream readouts","pmids":["18791164"],"is_preprint":false},{"year":2012,"finding":"Galactosylated IgG1 immune complexes promote association of FcγRIIB with dectin-1, leading to SHIP phosphorylation downstream of FcγRIIB and Syk downstream of dectin-1, which blocks C5aR-mediated ERK1/2 phosphorylation and suppresses complement-mediated inflammatory responses in vitro and in vivo; high IgG N-glycan galactosylation is required for FcγRIIB–dectin-1 association.","method":"Co-immunoprecipitation of FcγRIIB with dectin-1; SHIP and Syk phosphorylation assays; ERK1/2 phosphorylation; peritonitis and epidermolysis bullosa acquisita mouse models; glycan-manipulated IgG1","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP of FcγRIIB–dectin-1 complex; mechanistic signaling assays; in vivo disease models; glycan dependency established; multiple orthogonal methods","pmids":["22922409"],"is_preprint":false},{"year":2013,"finding":"FcγRIIB expressed in neurons mediates Aβ oligomer neurotoxicity in Alzheimer's disease: soluble Aβ oligomers interact directly with neuronal FcγRIIB, activating ER stress and caspase-12; Fcgr2b KO neurons are resistant to Aβ-induced cell death, and Fcgr2b deficiency rescues LTP inhibition and memory impairment in an AD mouse model.","method":"In vitro binding assay (Aβ–FcγRIIB interaction); Fcgr2b KO primary neurons; caspase-12/ER stress assays; LTP recordings; memory behavioral tests in AD mouse model","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct binding demonstrated, KO rescue across multiple functional readouts (cell death, LTP, memory), validated in both human AD tissue and mouse model","pmids":["23921129"],"is_preprint":false},{"year":2015,"finding":"TLR4 activation of monocytes by LPS induces MARCH3 (E3 ubiquitin ligase) upregulation, leading to ubiquitination of FcγRIIB protein and its downregulation; siRNA knockdown of MARCH3 prevents LPS-induced FcγRIIB loss.","method":"TLR agonist screening; ubiquitination assay of FcγRIIB in LPS-treated monocytes; MARCH3 siRNA knockdown; microarray-identified MARCH3 upregulation","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA epistasis identifies MARCH3 as the E3 ligase; ubiquitination assay confirms PTM; single lab, two orthogonal methods","pmids":["26694610"],"is_preprint":false},{"year":2015,"finding":"FcγRIIB mediates anti-CD28 superagonist TGN1412 activity: FcγRIIB expression on monocytes (which is logarithmically upregulated during high-density preculture) is necessary and sufficient for TGN1412-mediated T cell proliferation, acting by crosslinking the antibody.","method":"High-density vs low-density preculture PBMC assays; FcγRIIB expression measurement by flow cytometry; reconstitution experiments mixing FcγRIIB+ monocytes with LD T cells; B cell FcγRIIB functional assay","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reconstitution experiment with defined cell populations establishes FcγRIIB on monocytes as required effector; single lab, multiple cell manipulation approaches","pmids":["25395427"],"is_preprint":false},{"year":2015,"finding":"FcγRIIB mediates antigen-independent inhibition of human B cells (naïve B cells, memory B cells, and plasma cells) through Btk and p38 MAPK; FcγRIIB crosslinking eliminates antibody-secreting plasma cells and blocks naïve B cell proliferation without affecting memory B cell activation.","method":"FcγRIIB crosslinking on sorted human B cell subsets; Btk and p38 MAPK inhibitor assays; proliferation and differentiation assays","journal":"Journal of biomedical science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological pathway dissection (Btk and p38 inhibitors) in primary human cells; single lab; multiple B cell subsets tested","pmids":["26475492"],"is_preprint":false},{"year":2017,"finding":"FcγRIIB activation by hyposialylated IgG in endothelium impairs endothelial cell insulin transcytosis, reducing insulin delivery to skeletal muscle and causing obesity-induced insulin resistance; endothelium-specific FcγRIIB deletion protects mice from HFD-induced insulin resistance; IgG from T2DM patients is hyposialylated and causes insulin resistance via FcγRIIB.","method":"Global and endothelium-specific FcγRIIB KO mice; HFD model; IgG transfer into IgG-deficient mice; in vitro endothelial insulin transcytosis assay; IgG sialylation analysis","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific KO, adoptive IgG transfer, in vitro transcytosis mechanism, and human patient IgG validation provide convergent evidence; multiple orthogonal approaches","pmids":["29202472"],"is_preprint":false},{"year":2017,"finding":"IVIG attenuates post-ICH mast cell activation via the FcγRIIB/SHIP1/PIP3 pathway: FcγRIIB engagement activates SHIP1, hydrolyzing PIP3 and inhibiting calcium mobilization and mast cell degranulation; in vivo siRNA knockdown of SHIP1 abolishes IVIG's protective effects.","method":"ICH collagenase mouse model; siRNA-mediated in vivo SHIP1 knockdown; mast cell degranulation assays; brain edema and neurological function assessment","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo siRNA epistasis confirms SHIP1 as effector; single lab; functional neurological readouts validate pathway","pmids":["29138419"],"is_preprint":false},{"year":2018,"finding":"The I232T polymorphism in the transmembrane domain of FcγRIIB tilts the TM domain, bending the ectodomain toward the plasma membrane to allosterically impede ligand (IgG1/IgG2/IgG3) binding, reducing in situ 2D binding affinities and association rates by 3–4 fold.","method":"Single-cell FRET assay; molecular dynamics simulations; in situ 2D binding kinetics measurements","journal":"eLife (PMID 31343409, published 2019)","confidence":"High","confidence_rationale":"Tier 1 / Moderate — FRET structural assay combined with MD simulation and quantitative binding kinetics; mechanistic link from TM tilt to ectodomain conformation to ligand affinity established in one study","pmids":["31343409"],"is_preprint":false},{"year":2018,"finding":"FcγRIIB expressed in neurons acts as a receptor for α-synuclein fibrils and mediates cell-to-cell transmission (prion-like propagation) of α-syn; SHP-1 and SHP-2 are activated downstream of FcγRIIB by α-syn fibrils and are required for α-syn transmission and Lewy body-like inclusion formation.","method":"Co-culture neuronal transmission assay; FcγRIIB-blocking/KO experiments; SHP-1/SHP-2 phosphorylation assays; Lewy body-like inclusion quantification","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — receptor identity established by blockade/KO; downstream SHP-1/2 activation measured; single lab; co-culture system demonstrates transmission","pmids":["29298416"],"is_preprint":false},{"year":2019,"finding":"FcγRIIB differentially regulates B cell tolerance checkpoints: reduced FcγRIIB enhances deletion/anergy of autoreactive immature B cells (pre-immune checkpoint) but promotes autoreactive B cell expansion in germinal centers and autoantibody production (post-immune checkpoint), demonstrating opposing effects at distinct developmental stages.","method":"FcγRIIB-deficient and transgenic mice; B cell tolerance assays with defined autoreactive BCR models; germinal center analysis; autoantibody measurement","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic models at multiple B cell stages with defined autoreactive BCR transgenes; opposing effects at two checkpoints validated with multiple readouts","pmids":["31036800"],"is_preprint":false},{"year":2019,"finding":"Follicular dendritic cells (FDCs) upregulate FcγRIIB during germinal center (GC) formation; FDC-specific FcγRIIB deficiency leads to aberrant GC B cell selection, increased GC diversity (persistence of IgM+ clones, fewer IgH mutations), indicating FDCs modulate GC B cell selection via FcγRIIB.","method":"Stromal-specific FcγRIIB KO mice; AidCreERT2-confetti clonal tracking; GC B cell frequency and mutation analysis; autoreactive and foreign antigen immunization models","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific genetic KO with clonal tracking system; multiple antigen models; mechanistic dissection of FDC role in GC selection","pmids":["31775042"],"is_preprint":false},{"year":2020,"finding":"FcγRIIB is expressed on a subset of effector CD8+ T cells following activation; cell-intrinsic FcγRIIB signaling induces caspase-3/7-mediated apoptosis in CD8+ T cells upon engagement by its functional ligand fibrinogen-like protein 2 (Fgl2), thereby limiting CD8+ T cell accumulation; IgG is not required for this pathway.","method":"Fcgr2b cell-intrinsic KO CD8+ T cells; graft rejection and tumor models; caspase-3/7 apoptosis assay; Fgl2 binding assay; IgG-deficient mouse controls","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-intrinsic genetic deletion with adoptive transfer; Fgl2 identified as functional ligand; caspase-3/7 mechanism defined; multiple disease models; replicated across labs implied by IgG KO control","pmids":["31940267"],"is_preprint":false},{"year":2022,"finding":"FcγRIIB inhibits antibody-mediated target cell depletion through competition with activating FcγRs for antibody Fc binding, independently of ITIM signaling; ITIM-null FcγRIIB expressed on target or effector cells still impairs mAb-mediated depletion through three therapeutically relevant surface receptors (CD20, CD25, OX40).","method":"Human FcγRIIB transgenic models with ITIM-intact vs ITIM-mutant receptors on targets or effectors; in vivo tumor depletion assays; in vitro ADCP assays","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — ITIM-null knock-in genetic models definitively separate competition mechanism from ITIM signaling; multiple targets tested; both in vitro and in vivo validation","pmids":["35858562"],"is_preprint":false},{"year":2022,"finding":"FcγRIIB expression in marginal zone (MZ) B cells is highest among B cell subsets; high FcγRIIB expression limits MZ B cell activation, ERK phosphorylation, and calcium flux; B cell-conditional Fcgr2b KO leads to spontaneous IgG3 autoantibody increase driven by extrafollicular MZ B cell responses.","method":"Fcgr2b conditional KO mice; MZ B cell subset analysis by flow cytometry; ERK phosphorylation and calcium flux assays; Notch2/Fcgr2b double KO to eliminate MZ B cells","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with double-KO epistasis identifies MZ B cell as key cellular locus; multiple signaling readouts; human SLE validation","pmids":["35819855"],"is_preprint":false},{"year":2023,"finding":"FcγRIIB on CD8+ T cells limits responsiveness to PD-1 checkpoint inhibition in a cell-intrinsic, Fc-dependent manner: FcγRIIBpos CD8+ T cells show reduced response to PD-1 and CTLA-4 checkpoint inhibitors; conditional Fcgr2b deletion on tumor-specific CD8+ T cells improves checkpoint blockade response; Fc-devoid anti-PD-1 F(ab) restores FcγRIIBpos T cell proliferation.","method":"Conditional Fcgr2b KO on CD8+ T cells; Fc-devoid F(ab) anti-PD-1 comparison; in vivo B16, LLC, and MC38 tumor models; human melanoma patient FcγRIIBpos CD8+ T cell analysis","journal":"Science translational medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional genetic deletion, Fc-null antibody comparison, multiple tumor models, and human patient validation define a cell-intrinsic Fc-dependent mechanism","pmids":["37611081"],"is_preprint":false},{"year":2016,"finding":"CRP activates Smad3 via the CD32b–ERK/p38 MAP kinase crosstalk pathway (within 15 min, directly) and through TGF-β1 (at 24 h, indirectly); CRP also activates mTOR signaling via a Smad3-dependent mechanism (Smad3 physically binds mTOR); CD32b neutralizing antibody and Smad3 inhibitor abolish CRP-induced mTOR activation and renal fibrosis.","method":"CRPtg-db/db mouse model; in vitro renal tubular epithelial cell CRP stimulation; Smad3 inhibitor; CD32b neutralizing antibody; co-immunoprecipitation of Smad3 with mTOR; rapamycin treatment","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP of Smad3–mTOR complex; multiple inhibitors; in vivo and in vitro concordance; single lab","pmids":["27221338"],"is_preprint":false}],"current_model":"FcγRIIB (FCGR2B/CD32B) is the sole inhibitory IgG Fc receptor; upon co-ligation with activating receptors (BCR, FcεRI, Kit, activating FcγRs), its ITIM is phosphorylated by Src-family kinases, recruiting SHIP to hydrolyze PIP3 and suppress Akt/calcium signaling, while its transmembrane domain (disrupted by the I232T/I187T SLE-risk polymorphism) allosterically controls ligand binding affinity; FcγRIIB also crosslinks with dectin-1 in a galactosylated-IgG–dependent manner to suppress complement signaling, acts as a neuronal receptor for Aβ oligomers and α-synuclein fibrils triggering ER stress/SHP-1/2, mediates CRP inhibition of eNOS via PP2A in endothelium, induces apoptosis in plasma cells and CD8+ T cells (via Fgl2–caspase-3/7), limits CD8+ T cell responses to checkpoint inhibitors in an Fc-dependent cell-intrinsic manner, and is subject to ubiquitin-mediated downregulation by the E3 ligase MARCH3 upon TLR4 activation."},"narrative":{"mechanistic_narrative":"FcγRIIB (CD32B) is the inhibitory IgG Fc receptor that sets thresholds for immune-cell activation and tolerance, principally by co-clustering with activating immunoreceptors and dampening their downstream signaling [PMID:9242674, PMID:31036800]. Upon co-ligation with the B-cell antigen receptor, Kit, or other activating receptors, its phosphorylated ITIM recruits the inositol 5'-phosphatase SHIP rather than SHP-1; SHIP hydrolyzes PIP3, blocking Akt activation, calcium influx, and CD19 phosphorylation despite intact PI3K activity [PMID:9242674, PMID:10224144, PMID:12217398]. This SHIP-dependent module suppresses BCR-driven BLyS survival signaling, mast-cell proliferation and degranulation, and antigen-independent human B-cell responses through Btk and p38 MAPK [PMID:12217398, PMID:18791164, PMID:26475492, PMID:29138419]. The receptor's transmembrane domain independently tunes function: the SLE-associated I232T polymorphism tilts the TM helix, bending the ectodomain toward the membrane to allosterically reduce IgG binding affinity, while also altering ITIM-independent inhibition of BCR signaling [PMID:14613290, PMID:31343409]. FcγRIIB output is governed at the expression level through promoter polymorphisms that alter transcription-factor binding and receptor abundance [PMID:12370366, PMID:15153543], and post-translationally by TLR4-induced MARCH3-mediated ubiquitination and downregulation [PMID:26694610]. Beyond canonical inhibition, FcγRIIB acts as a pro-apoptotic and signaling receptor in multiple contexts: crosslinking eliminates bone-marrow plasma cells, plasmablasts, and myeloma cells, and engagement of the functional ligand FGL2 induces caspase-3/7 apoptosis in B cells and effector CD8+ T cells independently of IgG [PMID:17322888, PMID:18991288, PMID:31940267]. It restrains autoreactive B-cell selection within germinal centers, including on follicular dendritic cells and marginal-zone B cells [PMID:31036800, PMID:31775042, PMID:35819855], limits CD8+ T-cell responsiveness to PD-1/CTLA-4 checkpoint blockade in a cell-intrinsic Fc-dependent manner [PMID:37611081], and impairs therapeutic antibody-mediated target depletion by competing with activating FcγRs for Fc binding even without ITIM signaling [PMID:35858562]. FcγRIIB additionally functions outside the immune system as an endothelial and neuronal receptor: it mediates CRP-driven PP2A inhibition of eNOS and hyposialylated-IgG impairment of insulin transcytosis driving insulin resistance [PMID:16269657, PMID:29202472], crosslinks with dectin-1 in a galactosylated-IgG-dependent manner to suppress complement signaling [PMID:22922409], and binds Aβ oligomers and α-synuclein fibrils on neurons to trigger ER stress, caspase-12, and SHP-1/SHP-2 activation [PMID:23921129, PMID:29298416].","teleology":[{"year":1997,"claim":"Resolved which phosphatase executes FcγRIIB inhibition, establishing SHIP rather than SHP-1 as the effector recruited to the phosphorylated receptor in B cells.","evidence":"Co-IP of SHIP with FcγRIIB and calcium assays in SHP-1-deficient (motheaten) vs normal B cell lines","pmids":["9242674"],"confidence":"High","gaps":["Did not define which kinase phosphorylates the ITIM","Did not establish the lipid substrate consumed by SHIP"]},{"year":1999,"claim":"Defined the biochemical mechanism downstream of SHIP, showing it consumes PIP3 to block Akt despite normal PI3K activity.","evidence":"PIP3 measurement and Akt kinase assays in A20 B cells with catalytic-dead SHIP and SHIP-null comparisons","pmids":["10224144"],"confidence":"High","gaps":["Did not address SHIP-independent inhibitory branches","Restricted to B-cell context"]},{"year":2002,"claim":"Extended the inhibitory module beyond the BCR, showing FcγRIIB-SHIP suppresses Kit-driven mast cell proliferation and cell-cycle entry.","evidence":"Co-aggregation, cell cycle analysis, SHIP-null cells, and SHIP catalytic-domain chimeric receptors in mast cells","pmids":["12217398"],"confidence":"High","gaps":["Identity of the residual SHIP-independent inhibition unresolved"]},{"year":2002,"claim":"Linked receptor abundance to autoimmunity, showing a promoter polymorphism abolishing AP-4 binding lowers FcγRIIB in germinal-center B cells and raises IgG responses.","evidence":"Luciferase reporters, EMSA, and NZB-allele congenic mice","pmids":["12370366"],"confidence":"High","gaps":["Murine allele; human relevance addressed separately","Did not test causal link to overt autoantibody disease"]},{"year":2003,"claim":"Demonstrated that the transmembrane I232T/I187T polymorphism alters signaling independently of the ITIM, implicating the TM domain in receptor function.","evidence":"Reconstitution of allelic and ITIM-truncated constructs in FcγRIIB-negative B cells with CD19 phosphorylation and calcium assays","pmids":["14613290"],"confidence":"High","gaps":["Structural basis of the TM effect not defined","Single lab"]},{"year":2004,"claim":"Identified a human promoter haplotype that raises FcγRIIB expression and associates with SLE susceptibility.","evidence":"Luciferase reporters in B and myeloid lines plus case-control genetics in 600 Caucasians","pmids":["15153543"],"confidence":"Medium","gaps":["Single functional reporter method","Transcription factors mediating the difference not identified"]},{"year":2005,"claim":"Established a non-immune endothelial function, showing CRP signals via FcγRIIB to activate PP2A and blunt eNOS.","evidence":"PP2A siRNA, heterologous expression, and FcγRIIB KO mouse vascular conductance assays","pmids":["16269657"],"confidence":"High","gaps":["Direct CRP-FcγRIIB binding affinity not quantified","Coupling between receptor and PP2A activation undefined"]},{"year":2007,"claim":"Revealed a pro-apoptotic role, showing FcγRIIB crosslinking eliminates plasma cells and that lupus plasma cells escape by losing the receptor.","evidence":"Crosslinking apoptosis assays in mouse and human plasma cells/myeloma and lupus-prone mouse comparison","pmids":["17322888"],"confidence":"High","gaps":["Apoptotic signaling pathway not delineated","Endogenous ligand triggering apoptosis not identified here"]},{"year":2008,"claim":"Identified FGL2 as a direct FcγRIIB ligand mediating immunosuppression and DC tolerance.","evidence":"SPR binding, FcγRIIB-null cells, and skin allograft survival in KO mice","pmids":["18991288"],"confidence":"High","gaps":["Binding interface on receptor and ligand not mapped","Downstream apoptotic effectors not defined here"]},{"year":2008,"claim":"Dissected cell-autonomous roles, showing B-cell FcγRIIB controls autoimmunity while macrophage FcγRIIB affects infection outcome.","evidence":"Cell-type-specific transgenic overexpression with arthritis, SLE, and S. pneumoniae models","pmids":["18362174"],"confidence":"High","gaps":["Mechanism of macrophage-specific infection susceptibility unresolved"]},{"year":2008,"claim":"Connected FcγRIIB inhibition to B-cell survival, showing it dampens BLyS-receptor upregulation and downstream survival signals via SHIP1.","evidence":"B cell co-aggregation with SHIP1-deficient comparison and BLyS signaling readouts","pmids":["18791164"],"confidence":"Medium","gaps":["Single lab","Mechanism linking SHIP1 to BLyS receptor expression indirect"]},{"year":2012,"claim":"Uncovered a glycan-dependent partnership with dectin-1 that suppresses complement-driven inflammation.","evidence":"Reciprocal Co-IP, SHIP/Syk phosphorylation, glycan-manipulated IgG1, and in vivo disease models","pmids":["22922409"],"confidence":"High","gaps":["Stoichiometry of the FcγRIIB-dectin-1 complex unknown","Structural basis of galactose dependency undefined"]},{"year":2013,"claim":"Established FcγRIIB as a neuronal Aβ-oligomer receptor mediating Alzheimer's neurotoxicity.","evidence":"Aβ-FcγRIIB binding, KO neuron resistance, ER stress/caspase-12 assays, and LTP/memory rescue in AD mice","pmids":["23921129"],"confidence":"High","gaps":["Signaling between receptor and ER stress not fully mapped","Relationship to ITIM/SHIP module in neurons unclear"]},{"year":2015,"claim":"Identified MARCH3 as the E3 ligase downregulating FcγRIIB after TLR4 activation, defining post-translational regulation.","evidence":"Ubiquitination assays and MARCH3 siRNA in LPS-treated monocytes","pmids":["26694610"],"confidence":"Medium","gaps":["Single lab; ubiquitination site not mapped","Direct MARCH3-FcγRIIB interaction not shown"]},{"year":2015,"claim":"Showed FcγRIIB on monocytes is necessary and sufficient to crosslink the anti-CD28 superagonist TGN1412 and drive T-cell proliferation.","evidence":"Density-dependent FcγRIIB upregulation and monocyte/T-cell reconstitution in PBMC","pmids":["25395427"],"confidence":"Medium","gaps":["Single lab","Mechanism of density-driven upregulation not defined"]},{"year":2015,"claim":"Defined antigen-independent inhibition of human B-cell subsets through Btk and p38 MAPK with subset-selective effects.","evidence":"Crosslinking on sorted human B cell subsets with Btk and p38 inhibitor dissection","pmids":["26475492"],"confidence":"Medium","gaps":["Single lab","Relationship between Btk/p38 branch and SHIP branch unresolved"]},{"year":2016,"claim":"Linked CRP-FcγRIIB signaling to fibrosis via ERK/p38-Smad3-mTOR crosstalk.","evidence":"CRPtg-db/db mice, CD32b neutralizing antibody, Smad3 inhibitor, and Smad3-mTOR Co-IP","pmids":["27221338"],"confidence":"Medium","gaps":["Single lab","Direct receptor-to-Smad3 coupling not biochemically defined"]},{"year":2017,"claim":"Extended endothelial signaling to metabolism, showing hyposialylated IgG-FcγRIIB impairs insulin transcytosis and causes insulin resistance.","evidence":"Endothelium-specific KO mice, HFD, IgG transfer, in vitro transcytosis, and T2DM patient IgG","pmids":["29202472"],"confidence":"High","gaps":["Intracellular signaling controlling transcytosis not delineated","Glycan recognition mechanism on receptor unclear"]},{"year":2017,"claim":"Confirmed in vivo that the FcγRIIB/SHIP1/PIP3 axis controls mast cell degranulation, mediating IVIG therapeutic benefit after hemorrhage.","evidence":"ICH mouse model with in vivo SHIP1 siRNA knockdown and degranulation/neurological readouts","pmids":["29138419"],"confidence":"Medium","gaps":["Single lab","IgG species engaging FcγRIIB in vivo not defined"]},{"year":2018,"claim":"Provided a structural mechanism for the I232T polymorphism, showing TM tilt bends the ectodomain to reduce IgG binding affinity.","evidence":"Single-cell FRET, molecular dynamics, and in situ 2D binding kinetics","pmids":["31343409"],"confidence":"High","gaps":["Link between altered affinity and disease risk in vivo not demonstrated here"]},{"year":2018,"claim":"Identified FcγRIIB as a neuronal α-synuclein fibril receptor driving prion-like transmission via SHP-1/SHP-2.","evidence":"Co-culture transmission assay with FcγRIIB blockade/KO and SHP-1/2 phosphorylation","pmids":["29298416"],"confidence":"Medium","gaps":["Single lab","Direct fibril-receptor binding affinity not quantified"]},{"year":2019,"claim":"Demonstrated stage-dependent, opposing roles of FcγRIIB at pre- and post-immune B-cell tolerance checkpoints.","evidence":"Deficient and transgenic mice with defined autoreactive BCR models and germinal-center analysis","pmids":["31036800"],"confidence":"High","gaps":["Molecular basis of opposing effects at the two checkpoints unresolved"]},{"year":2019,"claim":"Showed FcγRIIB on follicular dendritic cells shapes germinal-center B-cell selection and clonal diversity.","evidence":"Stromal-specific KO with confetti clonal tracking and mutation analysis","pmids":["31775042"],"confidence":"High","gaps":["Signaling consequence of FDC FcγRIIB engagement not defined"]},{"year":2020,"claim":"Established a cell-intrinsic apoptotic pathway in CD8+ T cells, with Fgl2 triggering caspase-3/7 to limit T-cell accumulation independently of IgG.","evidence":"Cell-intrinsic Fcgr2b KO CD8+ T cells, Fgl2 binding, caspase assays, and IgG-deficient controls in graft/tumor models","pmids":["31940267"],"confidence":"High","gaps":["Signaling between FcγRIIB and caspase activation in T cells not mapped"]},{"year":2022,"claim":"Separated an ITIM-independent competition mechanism, showing FcγRIIB blocks therapeutic antibody depletion by sequestering Fc from activating FcγRs.","evidence":"ITIM-null knock-in transgenic models with in vivo depletion and ADCP assays across CD20, CD25, OX40","pmids":["35858562"],"confidence":"High","gaps":["Quantitative contribution of competition vs ITIM signaling in disease unclear"]},{"year":2022,"claim":"Identified marginal-zone B cells as a key cellular locus where high FcγRIIB restrains extrafollicular autoantibody responses.","evidence":"Conditional KO with Notch2 double-KO epistasis, signaling readouts, and human SLE validation","pmids":["35819855"],"confidence":"High","gaps":["Why MZ B cells express the highest FcγRIIB not explained"]},{"year":2023,"claim":"Showed FcγRIIB on CD8+ T cells limits checkpoint-inhibitor responsiveness in a cell-intrinsic, Fc-dependent manner.","evidence":"Conditional Fcgr2b KO, Fc-devoid anti-PD-1 F(ab), multiple tumor models, and human melanoma patient analysis","pmids":["37611081"],"confidence":"High","gaps":["Whether the Fc-dependent effect uses ITIM/SHIP or competition not resolved"]},{"year":null,"claim":"How the divergent FcγRIIB outputs—SHIP-dependent inhibition, ITIM-independent Fc competition, FGL2-driven apoptosis, and neuronal aggregate sensing—are mechanistically unified or selected in different cell types remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model linking ligand identity to choice of downstream effector","Switch between inhibitory and pro-apoptotic signaling undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0001618","term_label":"virus receptor activity","supporting_discovery_ids":[12,19]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,1,2,23]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,9,22]},{"term_id":"GO:0038024","term_label":"cargo receptor activity","supporting_discovery_ids":[23]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,4,18,6]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,7,20,22,25]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,2,6,11]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[7,22]}],"complexes":[],"partners":["SHIP","FGL2","CLEC7A","MARCH3"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P31994","full_name":"Low affinity immunoglobulin gamma Fc region receptor II-b","aliases":["CDw32","Fc-gamma RII-b","Fc-gamma-RIIb","FcRII-b"],"length_aa":310,"mass_kda":34.0,"function":"Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P31994/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FCGR2B","classification":"Not Classified","n_dependent_lines":30,"n_total_lines":1208,"dependency_fraction":0.024834437086092714},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FCGR2B","total_profiled":1310},"omim":[{"mim_id":"612169","title":"Fc FRAGMENT OF IgG RECEPTOR IIc; FCGR2C","url":"https://www.omim.org/entry/612169"},{"mim_id":"611162","title":"MALARIA, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/611162"},{"mim_id":"610665","title":"Fc FRAGMENT OF IgG RECEPTOR IIIb; FCGR3B","url":"https://www.omim.org/entry/610665"},{"mim_id":"606891","title":"Fc RECEPTOR-LIKE PROTEIN A; FCRLA","url":"https://www.omim.org/entry/606891"},{"mim_id":"605877","title":"Fc RECEPTOR-LIKE PROTEIN 5; FCRL5","url":"https://www.omim.org/entry/605877"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"placenta","ntpm":378.4}],"url":"https://www.proteinatlas.org/search/FCGR2B"},"hgnc":{"alias_symbol":["CD32","CD32B","FcgammaRIIb","FcGRIIB"],"prev_symbol":["FCG2","FCGR2"]},"alphafold":{"accession":"P31994","domains":[{"cath_id":"2.60.40.10","chopping":"52-130","consensus_level":"high","plddt":93.5444,"start":52,"end":130},{"cath_id":"2.60.40.10","chopping":"134-216","consensus_level":"high","plddt":97.6764,"start":134,"end":216}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P31994","model_url":"https://alphafold.ebi.ac.uk/files/AF-P31994-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P31994-F1-predicted_aligned_error_v6.png","plddt_mean":78.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FCGR2B","jax_strain_url":"https://www.jax.org/strain/search?query=FCGR2B"},"sequence":{"accession":"P31994","fasta_url":"https://rest.uniprot.org/uniprotkb/P31994.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P31994/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P31994"}},"corpus_meta":[{"pmid":"20414206","id":"PMC_20414206","title":"FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications.","date":"2010","source":"Nature reviews. Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20414206","citation_count":448,"is_preprint":false},{"pmid":"22922409","id":"PMC_22922409","title":"Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcγRIIB and dectin-1.","date":"2012","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22922409","citation_count":379,"is_preprint":false},{"pmid":"12115230","id":"PMC_12115230","title":"Fcgamma receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility.","date":"2002","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/12115230","citation_count":264,"is_preprint":false},{"pmid":"17322888","id":"PMC_17322888","title":"FcgammaRIIb controls bone marrow plasma cell persistence and apoptosis.","date":"2007","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17322888","citation_count":236,"is_preprint":false},{"pmid":"15153543","id":"PMC_15153543","title":"A promoter haplotype of the immunoreceptor tyrosine-based inhibitory motif-bearing FcgammaRIIb alters receptor expression and associates with autoimmunity. I. Regulatory FCGR2B polymorphisms and their association with systemic lupus erythematosus.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15153543","citation_count":141,"is_preprint":false},{"pmid":"14613290","id":"PMC_14613290","title":"A novel polymorphism in the Fcgamma receptor IIB (CD32B) transmembrane region alters receptor signaling.","date":"2003","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/14613290","citation_count":137,"is_preprint":false},{"pmid":"19309690","id":"PMC_19309690","title":"Copy number variation at the FCGR locus includes FCGR3A, FCGR2C and FCGR3B but not FCGR2A and FCGR2B.","date":"2009","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/19309690","citation_count":131,"is_preprint":false},{"pmid":"18362174","id":"PMC_18362174","title":"Distinct cell-specific control of autoimmunity and infection by FcgammaRIIb.","date":"2008","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18362174","citation_count":127,"is_preprint":false},{"pmid":"21357255","id":"PMC_21357255","title":"Antibody-mediated coengagement of FcγRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus.","date":"2011","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/21357255","citation_count":119,"is_preprint":false},{"pmid":"25873171","id":"PMC_25873171","title":"Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo.","date":"2015","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/25873171","citation_count":116,"is_preprint":false},{"pmid":"17386079","id":"PMC_17386079","title":"Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization.","date":"2007","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17386079","citation_count":115,"is_preprint":false},{"pmid":"23921129","id":"PMC_23921129","title":"FcγRIIb mediates amyloid-β neurotoxicity and memory impairment in Alzheimer's disease.","date":"2013","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/23921129","citation_count":108,"is_preprint":false},{"pmid":"31940267","id":"PMC_31940267","title":"Signaling through the Inhibitory Fc Receptor FcγRIIB Induces CD8+ T Cell Apoptosis to Limit T Cell Immunity.","date":"2020","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/31940267","citation_count":96,"is_preprint":false},{"pmid":"16269657","id":"PMC_16269657","title":"FcgammaRIIB mediates C-reactive protein inhibition of endothelial NO synthase.","date":"2005","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/16269657","citation_count":90,"is_preprint":false},{"pmid":"18991288","id":"PMC_18991288","title":"The FGL2-FcgammaRIIB pathway: a novel mechanism leading to immunosuppression.","date":"2008","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18991288","citation_count":89,"is_preprint":false},{"pmid":"29202472","id":"PMC_29202472","title":"Hyposialylated IgG activates endothelial IgG receptor FcγRIIB to promote obesity-induced insulin resistance.","date":"2017","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/29202472","citation_count":86,"is_preprint":false},{"pmid":"12370366","id":"PMC_12370366","title":"Transcriptional regulation of Fcgr2b gene by polymorphic promoter region and its contribution to humoral immune responses.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12370366","citation_count":82,"is_preprint":false},{"pmid":"28479335","id":"PMC_28479335","title":"Allergen-specific IgG antibody signaling through FcγRIIb promotes food tolerance.","date":"2017","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28479335","citation_count":80,"is_preprint":false},{"pmid":"20007534","id":"PMC_20007534","title":"IFN regulatory factor 5 is required for disease development in the FcgammaRIIB-/-Yaa and FcgammaRIIB-/- mouse models of systemic lupus erythematosus.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/20007534","citation_count":80,"is_preprint":false},{"pmid":"20146709","id":"PMC_20146709","title":"FcgammaRIIB, FcgammaRIIIB, and systemic lupus erythematosus.","date":"2010","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/20146709","citation_count":79,"is_preprint":false},{"pmid":"22257644","id":"PMC_22257644","title":"Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody.","date":"2012","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22257644","citation_count":77,"is_preprint":false},{"pmid":"16757681","id":"PMC_16757681","title":"CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16757681","citation_count":66,"is_preprint":false},{"pmid":"24227819","id":"PMC_24227819","title":"Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity.","date":"2013","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/24227819","citation_count":66,"is_preprint":false},{"pmid":"26683154","id":"PMC_26683154","title":"FcγRIIB and autoimmunity.","date":"2016","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/26683154","citation_count":65,"is_preprint":false},{"pmid":"27221338","id":"PMC_27221338","title":"C-Reactive Protein Promotes Diabetic Kidney Disease in db/db Mice via the CD32b-Smad3-mTOR signaling Pathway.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27221338","citation_count":60,"is_preprint":false},{"pmid":"29298416","id":"PMC_29298416","title":"Prion-like Propagation of α-Synuclein Is Regulated by the FcγRIIB-SHP-1/2 Signaling Pathway in Neurons.","date":"2018","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/29298416","citation_count":60,"is_preprint":false},{"pmid":"32956626","id":"PMC_32956626","title":"DPP4/CD32b/NF-κB Circuit: A Novel Druggable Target for Inhibiting CRP-Driven Diabetic Nephropathy.","date":"2020","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32956626","citation_count":57,"is_preprint":false},{"pmid":"20506263","id":"PMC_20506263","title":"Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold.","date":"2010","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/20506263","citation_count":55,"is_preprint":false},{"pmid":"34248948","id":"PMC_34248948","title":"Acute Kidney Injury Induced Lupus Exacerbation Through the Enhanced Neutrophil Extracellular Traps (and Apoptosis) in Fcgr2b Deficient Lupus Mice With Renal Ischemia Reperfusion Injury.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34248948","citation_count":52,"is_preprint":false},{"pmid":"9242674","id":"PMC_9242674","title":"Protein-tyrosine phosphatase SHP-1 is dispensable for FcgammaRIIB-mediated inhibition of B cell antigen receptor activation.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9242674","citation_count":52,"is_preprint":false},{"pmid":"17133580","id":"PMC_17133580","title":"The functional variant of the inhibitory Fcgamma receptor IIb (CD32B) is associated with the rate of radiologic joint damage and dendritic cell function in rheumatoid arthritis.","date":"2006","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/17133580","citation_count":51,"is_preprint":false},{"pmid":"10224144","id":"PMC_10224144","title":"FcgammaRIIb modulation of surface immunoglobulin-induced Akt activation in murine B cells.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10224144","citation_count":50,"is_preprint":false},{"pmid":"24285839","id":"PMC_24285839","title":"Cutting edge: Expression of FcγRIIB tempers memory CD8 T cell function in vivo.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/24285839","citation_count":49,"is_preprint":false},{"pmid":"25395427","id":"PMC_25395427","title":"Upregulation of FcγRIIb on monocytes is necessary to promote the superagonist activity of TGN1412.","date":"2014","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/25395427","citation_count":49,"is_preprint":false},{"pmid":"31681256","id":"PMC_31681256","title":"The Complex Association of FcγRIIb With Autoimmune Susceptibility.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31681256","citation_count":48,"is_preprint":false},{"pmid":"18390752","id":"PMC_18390752","title":"FcgammaRIIB deficiency leads to autoimmunity and a defective response to apoptosis in Mrl-MpJ mice.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18390752","citation_count":48,"is_preprint":false},{"pmid":"24442430","id":"PMC_24442430","title":"CD19 and CD32b differentially regulate human B cell responsiveness.","date":"2014","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/24442430","citation_count":46,"is_preprint":false},{"pmid":"20097865","id":"PMC_20097865","title":"FcgammaRIIB inhibits the development of atherosclerosis in low-density lipoprotein receptor-deficient mice.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/20097865","citation_count":46,"is_preprint":false},{"pmid":"30930905","id":"PMC_30930905","title":"Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy-Focus on FcγRIIB.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30930905","citation_count":42,"is_preprint":false},{"pmid":"16352741","id":"PMC_16352741","title":"Hydronephrosis associated with antiurothelial and antinuclear autoantibodies in BALB/c-Fcgr2b-/-Pdcd1-/- mice.","date":"2005","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16352741","citation_count":41,"is_preprint":false},{"pmid":"27997998","id":"PMC_27997998","title":"A novel bispecific DARPin targeting FcγRIIB and FcεRI-bound IgE inhibits allergic responses.","date":"2017","source":"Allergy","url":"https://pubmed.ncbi.nlm.nih.gov/27997998","citation_count":40,"is_preprint":false},{"pmid":"17521421","id":"PMC_17521421","title":"High synovial expression of the inhibitory FcgammaRIIb in rheumatoid arthritis.","date":"2007","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/17521421","citation_count":38,"is_preprint":false},{"pmid":"32927460","id":"PMC_32927460","title":"Syk Inhibitor Attenuates Polymicrobial Sepsis in FcgRIIb-Deficient Lupus Mouse Model, the Impact of Lupus Characteristics in Sepsis.","date":"2020","source":"Journal of innate immunity","url":"https://pubmed.ncbi.nlm.nih.gov/32927460","citation_count":37,"is_preprint":false},{"pmid":"31514375","id":"PMC_31514375","title":"Lipocalin-2 (Lcn-2) Attenuates Polymicrobial Sepsis with LPS Preconditioning (LPS Tolerance) in FcGRIIb Deficient Lupus Mice.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/31514375","citation_count":36,"is_preprint":false},{"pmid":"17713556","id":"PMC_17713556","title":"Expression of the autoimmune Fcgr2b NZW allele fails to be upregulated in germinal center B cells and is associated with increased IgG production.","date":"2007","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/17713556","citation_count":36,"is_preprint":false},{"pmid":"18216299","id":"PMC_18216299","title":"CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18216299","citation_count":35,"is_preprint":false},{"pmid":"34103965","id":"PMC_34103965","title":"A Synergy Between Endotoxin and (1→3)-Beta-D-Glucan Enhanced Neutrophil Extracellular Traps in Candida Administered Dextran Sulfate Solution Induced Colitis in FcGRIIB-/- Lupus Mice, an Impact of Intestinal Fungi in Lupus.","date":"2021","source":"Journal of inflammation research","url":"https://pubmed.ncbi.nlm.nih.gov/34103965","citation_count":35,"is_preprint":false},{"pmid":"31775042","id":"PMC_31775042","title":"Follicular Dendritic Cells Modulate Germinal Center B Cell Diversity through FcγRIIB.","date":"2019","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/31775042","citation_count":35,"is_preprint":false},{"pmid":"32582149","id":"PMC_32582149","title":"Dysregulation of Lipid Metabolism in Macrophages Is Responsible for Severe Endotoxin Tolerance in FcgRIIB-Deficient Lupus Mice.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32582149","citation_count":34,"is_preprint":false},{"pmid":"11753646","id":"PMC_11753646","title":"Deregulation of FCGR2B expression by 1q21 rearrangements in follicular lymphomas.","date":"2001","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11753646","citation_count":33,"is_preprint":false},{"pmid":"28960214","id":"PMC_28960214","title":"Upregulation of FcγRIIB by resveratrol via NF-κB activation reduces B-cell numbers and ameliorates lupus.","date":"2017","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28960214","citation_count":33,"is_preprint":false},{"pmid":"22760702","id":"PMC_22760702","title":"Development and characterisation of monoclonal antibodies specific for the murine inhibitory FcγRIIB (CD32B).","date":"2012","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22760702","citation_count":32,"is_preprint":false},{"pmid":"33573095","id":"PMC_33573095","title":"Prominent Indomethacin-Induced Enteropathy in Fcgriib Defi-cient lupus Mice: An Impact of Macrophage Responses and Immune Deposition in Gut.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33573095","citation_count":32,"is_preprint":false},{"pmid":"14647193","id":"PMC_14647193","title":"FcgammaRIIB gene polymorphisms in Japanese periodontitis patients.","date":"2003","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/14647193","citation_count":32,"is_preprint":false},{"pmid":"32700597","id":"PMC_32700597","title":"Syk inhibitor attenuates inflammation in lupus mice from FcgRIIb deficiency but not in pristane induction: the influence of lupus pathogenesis on the therapeutic effect.","date":"2020","source":"Lupus","url":"https://pubmed.ncbi.nlm.nih.gov/32700597","citation_count":32,"is_preprint":false},{"pmid":"38147316","id":"PMC_38147316","title":"FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment.","date":"2024","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/38147316","citation_count":31,"is_preprint":false},{"pmid":"29928276","id":"PMC_29928276","title":"Tissue-Specific Expression of the Low-Affinity IgG Receptor, FcγRIIb, on Human Mast Cells.","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29928276","citation_count":31,"is_preprint":false},{"pmid":"29406570","id":"PMC_29406570","title":"New revelations from an old receptor: Immunoregulatory functions of the inhibitory Fc gamma receptor, FcγRIIB (CD32B).","date":"2018","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/29406570","citation_count":30,"is_preprint":false},{"pmid":"18791164","id":"PMC_18791164","title":"FcgammaRIIB signals inhibit BLyS signaling and BCR-mediated BLyS receptor up-regulation.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18791164","citation_count":30,"is_preprint":false},{"pmid":"12217398","id":"PMC_12217398","title":"Negative regulation of mast cell proliferation by FcgammaRIIB.","date":"2002","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12217398","citation_count":30,"is_preprint":false},{"pmid":"24026082","id":"PMC_24026082","title":"Immunotherapy targeting inhibitory Fcγ receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/24026082","citation_count":29,"is_preprint":false},{"pmid":"24734927","id":"PMC_24734927","title":"Regulation of IgE-mediated signalling in human basophils by CD32b and its role in Syk down-regulation: basic mechanisms in allergic disease.","date":"2014","source":"Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24734927","citation_count":29,"is_preprint":false},{"pmid":"35392965","id":"PMC_35392965","title":"HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy.","date":"2022","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/35392965","citation_count":29,"is_preprint":false},{"pmid":"31560714","id":"PMC_31560714","title":"IGFBP2 promotes immunosuppression associated with its mesenchymal induction and FcγRIIB phosphorylation in glioblastoma.","date":"2019","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/31560714","citation_count":29,"is_preprint":false},{"pmid":"33616086","id":"PMC_33616086","title":"FcγRIIB is a T cell checkpoint in antitumor immunity.","date":"2021","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/33616086","citation_count":27,"is_preprint":false},{"pmid":"17202351","id":"PMC_17202351","title":"FcgammaRIIB regulates autoreactive primary antibody-forming cell, but not germinal center B cell, activity.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17202351","citation_count":27,"is_preprint":false},{"pmid":"30889825","id":"PMC_30889825","title":"Decreased Protein Kinase C-β Type II Associated with the Prominent Endotoxin Exhaustion in the Macrophage of FcGRIIb-/- Lupus Prone Mice is Revealed by Phosphoproteomic Analysis.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30889825","citation_count":26,"is_preprint":false},{"pmid":"19640933","id":"PMC_19640933","title":"FCGR2B gene polymorphism rather than FCGR2A, FCGR3A and FCGR3B is associated with anti-GBM disease in Chinese.","date":"2009","source":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","url":"https://pubmed.ncbi.nlm.nih.gov/19640933","citation_count":26,"is_preprint":false},{"pmid":"25116108","id":"PMC_25116108","title":"FcγRIIB as a key determinant of agonistic antibody efficacy.","date":"2014","source":"Current topics in microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25116108","citation_count":26,"is_preprint":false},{"pmid":"31036800","id":"PMC_31036800","title":"FcγRIIb differentially regulates pre-immune and germinal center B cell tolerance in mouse and human.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31036800","citation_count":26,"is_preprint":false},{"pmid":"23593433","id":"PMC_23593433","title":"FCGR2B and FCRLB gene polymorphisms associated with IgA nephropathy.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23593433","citation_count":25,"is_preprint":false},{"pmid":"22390489","id":"PMC_22390489","title":"FcγRIIB: a modulator of cell activation and humoral tolerance.","date":"2012","source":"Expert review of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22390489","citation_count":25,"is_preprint":false},{"pmid":"22516957","id":"PMC_22516957","title":"FcγRIIb and BAFF differentially regulate peritoneal B1 cell survival.","date":"2012","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/22516957","citation_count":25,"is_preprint":false},{"pmid":"35819855","id":"PMC_35819855","title":"FcγRIIB regulates autoantibody responses by limiting marginal zone B cell activation.","date":"2022","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/35819855","citation_count":24,"is_preprint":false},{"pmid":"29138419","id":"PMC_29138419","title":"IVIG activates FcγRIIB-SHIP1-PIP3 Pathway to stabilize mast cells and suppress inflammation after ICH in mice.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29138419","citation_count":24,"is_preprint":false},{"pmid":"29497990","id":"PMC_29497990","title":"Transmembrane domain dependent inhibitory function of FcγRIIB.","date":"2018","source":"Protein & cell","url":"https://pubmed.ncbi.nlm.nih.gov/29497990","citation_count":23,"is_preprint":false},{"pmid":"31343409","id":"PMC_31343409","title":"FcγRIIB-I232T polymorphic change allosterically suppresses ligand binding.","date":"2019","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/31343409","citation_count":23,"is_preprint":false},{"pmid":"26475492","id":"PMC_26475492","title":"FcγRIIB mediates antigen-independent inhibition on human B lymphocytes through Btk and p38 MAPK.","date":"2015","source":"Journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/26475492","citation_count":23,"is_preprint":false},{"pmid":"35858562","id":"PMC_35858562","title":"FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/35858562","citation_count":22,"is_preprint":false},{"pmid":"20809520","id":"PMC_20809520","title":"FcγRIIB regulation of BCR/TLR-dependent autoreactive B-cell responses.","date":"2010","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20809520","citation_count":21,"is_preprint":false},{"pmid":"15572393","id":"PMC_15572393","title":"Intravenous immunoglobulin does not increase FcgammaRIIB expression on monocytes/macrophages during acute Kawasaki disease.","date":"2004","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/15572393","citation_count":21,"is_preprint":false},{"pmid":"37844994","id":"PMC_37844994","title":"C-reactive protein impairs immune response of CD8+ T cells via FcγRIIb-p38MAPK-ROS axis in multiple myeloma.","date":"2023","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37844994","citation_count":20,"is_preprint":false},{"pmid":"24869670","id":"PMC_24869670","title":"FcγRIIB regulates T-cell autoreactivity, ANCA production, and neutrophil activation to suppress anti-myeloperoxidase glomerulonephritis.","date":"2014","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/24869670","citation_count":20,"is_preprint":false},{"pmid":"21360699","id":"PMC_21360699","title":"Immune complex enhances tolerogenecity of immature dendritic cells via FcγRIIb and promotes FcγRIIb-overexpressing dendritic cells to attenuate lupus.","date":"2011","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21360699","citation_count":20,"is_preprint":false},{"pmid":"23054650","id":"PMC_23054650","title":"Low expression of FCGRIIB in macrophages of immune thrombocytopenia-affected individuals.","date":"2012","source":"International journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/23054650","citation_count":19,"is_preprint":false},{"pmid":"33919603","id":"PMC_33919603","title":"Lipopolysaccharide-Enhanced Responses against Aryl Hydrocarbon Receptor in FcgRIIb-Deficient Macrophages, a Profound Impact of an Environmental Toxin on a Lupus-Like Mouse Model.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33919603","citation_count":19,"is_preprint":false},{"pmid":"37611081","id":"PMC_37611081","title":"FcγRIIB expressed on CD8+ T cells limits responsiveness to PD-1 checkpoint inhibition in cancer.","date":"2023","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37611081","citation_count":19,"is_preprint":false},{"pmid":"25368023","id":"PMC_25368023","title":"IgG receptor FcγRIIB plays a key role in obesity-induced hypertension.","date":"2014","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/25368023","citation_count":19,"is_preprint":false},{"pmid":"14675408","id":"PMC_14675408","title":"FcgammaRIIB is differentially expressed during B cell maturation and in B-cell lymphomas.","date":"2004","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/14675408","citation_count":19,"is_preprint":false},{"pmid":"26694610","id":"PMC_26694610","title":"Toll-like Receptor 4 Ligands Down-regulate Fcγ Receptor IIb (FcγRIIb) via MARCH3 Protein-mediated Ubiquitination.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26694610","citation_count":19,"is_preprint":false},{"pmid":"32900860","id":"PMC_32900860","title":"FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells.","date":"2020","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32900860","citation_count":19,"is_preprint":false},{"pmid":"35865955","id":"PMC_35865955","title":"Antibody-Targeted TNFRSF Activation for Cancer Immunotherapy: The Role of FcγRIIB Cross-Linking.","date":"2022","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35865955","citation_count":18,"is_preprint":false},{"pmid":"38492222","id":"PMC_38492222","title":"Clec12A, CD301b, and FcγRIIB/III define the heterogeneity of murine DC2s and DC3s.","date":"2024","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/38492222","citation_count":17,"is_preprint":false},{"pmid":"36822164","id":"PMC_36822164","title":"The CD16 and CD32b Fc-gamma receptors regulate antibody-mediated responses in mouse natural killer cells.","date":"2023","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/36822164","citation_count":17,"is_preprint":false},{"pmid":"19327966","id":"PMC_19327966","title":"Selective regulation of autoreactive B cells by FcgammaRIIB.","date":"2009","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/19327966","citation_count":17,"is_preprint":false},{"pmid":"23686494","id":"PMC_23686494","title":"CD40 mediates downregulation of CD32B on specific memory B cell populations in rheumatoid arthritis.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/23686494","citation_count":16,"is_preprint":false},{"pmid":"26974714","id":"PMC_26974714","title":"Immunohistochemical detection of CD14 and combined assessment with CD32B and CD68 for wound age estimation.","date":"2016","source":"Forensic science international","url":"https://pubmed.ncbi.nlm.nih.gov/26974714","citation_count":16,"is_preprint":false},{"pmid":"32154641","id":"PMC_32154641","title":"Memory T cell-mediated rejection is mitigated by FcγRIIB expression on CD8+ T cells.","date":"2020","source":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","url":"https://pubmed.ncbi.nlm.nih.gov/32154641","citation_count":16,"is_preprint":false},{"pmid":"22244885","id":"PMC_22244885","title":"Increased incidence of anti-GBM disease in Fcgamma receptor 2b deficient mice, but not mice with conditional deletion of Fcgr2b on either B cells or myeloid cells alone.","date":"2012","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22244885","citation_count":16,"is_preprint":false},{"pmid":"30456753","id":"PMC_30456753","title":"Increased susceptibility against Cryptococcus neoformans of lupus mouse models (pristane-induction and FcGRIIb deficiency) is associated with activated macrophage, regardless of genetic background.","date":"2018","source":"Journal of microbiology (Seoul, Korea)","url":"https://pubmed.ncbi.nlm.nih.gov/30456753","citation_count":16,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53437,"output_tokens":7533,"usd":0.136653,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17221,"output_tokens":6798,"usd":0.128027,"stage2_stop_reason":"end_turn"},"total_usd":0.26468,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"SHP-1 is dispensable for FcγRIIB-mediated inhibition of B cell antigen receptor (sIgM) signaling; instead, SHIP (inositol 5'-phosphatase) is recruited to tyrosyl-phosphorylated FcγRIIB and mediates inhibition of calcium influx and CD19 dephosphorylation in B cells.\",\n      \"method\": \"Immortalized B cell lines from motheaten (SHP-1-deficient) mice and normal littermates; co-ligation of FcγRIIB and sIgM; calcium influx assays; co-immunoprecipitation of SHIP with FcγRIIB\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP and functional calcium assays in defined genetic KO cell lines; finding independently corroborated by parallel mast cell studies\",\n      \"pmids\": [\"9242674\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"FcγRIIB co-ligation with the B cell antigen receptor suppresses Akt activation by reducing PIP3 accumulation via SHIP-mediated hydrolysis, despite normal PI3K activation; SHIP acts downstream of FcγRIIB to consume PIP3 and block Akt.\",\n      \"method\": \"A20 murine B cell line; sIg-FcγRIIB co-clustering; PIP3 measurement; Akt kinase assays; comparison with SHIP-deficient avian B cells and fibroblasts expressing catalytically active vs. inactive SHIP\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro enzymatic mechanism established with catalytic-dead SHIP mutant, SHIP-null cells, and direct PIP3 measurement; multiple orthogonal approaches in one study\",\n      \"pmids\": [\"10224144\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"FcγRIIB negatively regulates mast cell proliferation when co-aggregated with Kit (SCF receptor): inhibits G1 entry, cyclins D2/D3/A induction, ERK/JNK/p38 activation, and Akt phosphorylation via SHIP recruitment; SHIP-null cells lose Akt and ERK inhibition but retain partial proliferation inhibition; a chimeric FcγRIIB bearing SHIP's catalytic domain mimics full inhibition.\",\n      \"method\": \"Mast cell co-aggregation assays; thymidine incorporation; cell cycle analysis; SHIP co-precipitation with FcγRIIB; SHIP-/- cells; chimeric receptor constructs\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods (KO cells, chimeric constructs, cell cycle, kinase assays) in one study; catalytic-domain replacement validates SHIP as key effector\",\n      \"pmids\": [\"12217398\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"A 13-nt deletion polymorphism in the Fcgr2b promoter found in autoimmune-prone NZB mice abolishes AP-4 transcription factor binding, reducing FcγRIIB1 expression in germinal center B cells and increasing IgG antibody responses.\",\n      \"method\": \"Luciferase reporter assays; EMSA and Southwestern analysis for AP-4 binding; congenic C57BL/6 mice carrying NZB Fcgr2b allele\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — promoter-reporter assay with EMSA identification of AP-4 as the relevant transcription factor, complemented by in vivo congenic mouse data; single lab, two orthogonal methods\",\n      \"pmids\": [\"12370366\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The I232T (Ile187Thr in earlier numbering) transmembrane domain polymorphism of FcγRIIB alters receptor signaling: the 187T allele mediates greater CD19 dephosphorylation and stronger inhibition of BCR-induced calcium response than 187I, independently of the ITIM, when co-engaged with BCR; both alleles similarly modulate BCR-induced and anti-Fas-induced apoptosis.\",\n      \"method\": \"Expression of both allelic forms (full-length and ITIM-truncated) in FcγRIIB-negative IIA1.6 mouse B cell line; CD19 phosphorylation assays; calcium flux assays; apoptosis assays\",\n      \"journal\": \"Arthritis and rheumatism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstitution in null cell line with truncated-domain constructs isolates transmembrane contribution; multiple functional assays; single lab\",\n      \"pmids\": [\"14613290\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"A less-frequent FCGR2B promoter haplotype drives increased expression of FcγRIIB in luciferase reporter assays in both B lymphoid and myeloid cell lines under constitutive and stimulated conditions, and is associated with SLE susceptibility.\",\n      \"method\": \"Luciferase reporter assays; identification of 10 novel SNPs; case-control genetic study in 600 Caucasians\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional reporter assay establishes promoter activity difference; single lab, one functional method complemented by genetic association\",\n      \"pmids\": [\"15153543\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"FcγRIIB mediates CRP inhibition of endothelial NO synthase (eNOS): CRP signals through FcγRIIB expressed in endothelium to activate PP2A, blunting eNOS phosphorylation at Ser1179 and impairing vasodilatation in vivo.\",\n      \"method\": \"Cultured endothelium; siRNA knockdown of PP2A; heterologous FcγRIIB expression; FcγRIIB+/+ vs FcγRIIB-/- mice with acetylcholine vascular conductance assays; aggregated IgG as FcγR ligand\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — siRNA knockdown, heterologous expression, and in vivo KO mouse vascular function assays all converge on FcγRIIB–PP2A–eNOS mechanism; multiple orthogonal approaches\",\n      \"pmids\": [\"16269657\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"FcγRIIB is expressed on bone marrow plasma cells; crosslinking FcγRIIB on plasma cells induces apoptosis, controlling their persistence in the bone marrow. Plasma cells from lupus-prone mice lack FcγRIIB expression and are protected from apoptosis. Human plasmablasts and FcγRIIB-expressing myeloma cells are also killed by FcγRIIB crosslinking.\",\n      \"method\": \"Flow cytometry of plasma cell FcγRIIB expression; crosslinking antibody-induced apoptosis assays; comparison between wild-type and lupus-prone mouse plasma cells; human plasmablast and myeloma cell assays\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct crosslinking functional assay in both mouse and human cells; in vivo genetic model; multiple cell types tested; replicated across species\",\n      \"pmids\": [\"17322888\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Cell-type-specific overexpression of FcγRIIB reveals distinct roles: B cell overexpression reduces IgG responses and ameliorates collagen-induced arthritis and SLE; macrophage overexpression has no effect on autoimmunity but increases mortality after S. pneumoniae infection.\",\n      \"method\": \"Transgenic mice overexpressing FcγRIIB under B cell- or macrophage-specific promoters; T-dependent immune response assays; collagen-induced arthritis model; S. pneumoniae infection model\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific transgenic dissection with multiple disease models; defines differential cell-autonomous roles; single lab, multiple orthogonal in vivo readouts\",\n      \"pmids\": [\"18362174\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"FGL2 (fibrinogen-like protein 2) binds specifically to FcγRIIB and FcγRIII on APC surfaces; FcγRIIB binding mediates FGL2-induced inhibition of DC maturation and apoptosis of FcγRIIB+ B cells; FcγRIIB is required for FGL2's immunosuppressive and allograft-prolonging effects in vivo.\",\n      \"method\": \"Flow cytometry and surface plasmon resonance for FGL2–FcγRIIB binding; FcγRIIB-/- vs wild-type BMDC maturation assays; A20 vs A20IIA1.6 (FcγRIIB-negative) apoptosis assay; skin allograft survival in FcγRIIB+/+ vs FcγRIIB-/- mice\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — SPR establishes direct binding; multiple functional assays in null cell line and KO mice; two orthogonal binding methods plus in vivo validation\",\n      \"pmids\": [\"18991288\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"FcγRIIB co-aggregation with BCR dampens BCR-induced BLyS receptor upregulation in a SHIP1-dependent manner, subsequently attenuating BLyS survival signals (Pim-2, non-canonical NF-κB, Bcl-xL) in B cells.\",\n      \"method\": \"B cell co-aggregation assays; BLyS receptor expression and signaling assays; SHIP1-deficient cells; pharmacological dissection\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional co-ligation assay with SHIP1-deficient comparison; single lab, two orthogonal downstream readouts\",\n      \"pmids\": [\"18791164\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Galactosylated IgG1 immune complexes promote association of FcγRIIB with dectin-1, leading to SHIP phosphorylation downstream of FcγRIIB and Syk downstream of dectin-1, which blocks C5aR-mediated ERK1/2 phosphorylation and suppresses complement-mediated inflammatory responses in vitro and in vivo; high IgG N-glycan galactosylation is required for FcγRIIB–dectin-1 association.\",\n      \"method\": \"Co-immunoprecipitation of FcγRIIB with dectin-1; SHIP and Syk phosphorylation assays; ERK1/2 phosphorylation; peritonitis and epidermolysis bullosa acquisita mouse models; glycan-manipulated IgG1\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP of FcγRIIB–dectin-1 complex; mechanistic signaling assays; in vivo disease models; glycan dependency established; multiple orthogonal methods\",\n      \"pmids\": [\"22922409\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"FcγRIIB expressed in neurons mediates Aβ oligomer neurotoxicity in Alzheimer's disease: soluble Aβ oligomers interact directly with neuronal FcγRIIB, activating ER stress and caspase-12; Fcgr2b KO neurons are resistant to Aβ-induced cell death, and Fcgr2b deficiency rescues LTP inhibition and memory impairment in an AD mouse model.\",\n      \"method\": \"In vitro binding assay (Aβ–FcγRIIB interaction); Fcgr2b KO primary neurons; caspase-12/ER stress assays; LTP recordings; memory behavioral tests in AD mouse model\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct binding demonstrated, KO rescue across multiple functional readouts (cell death, LTP, memory), validated in both human AD tissue and mouse model\",\n      \"pmids\": [\"23921129\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TLR4 activation of monocytes by LPS induces MARCH3 (E3 ubiquitin ligase) upregulation, leading to ubiquitination of FcγRIIB protein and its downregulation; siRNA knockdown of MARCH3 prevents LPS-induced FcγRIIB loss.\",\n      \"method\": \"TLR agonist screening; ubiquitination assay of FcγRIIB in LPS-treated monocytes; MARCH3 siRNA knockdown; microarray-identified MARCH3 upregulation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA epistasis identifies MARCH3 as the E3 ligase; ubiquitination assay confirms PTM; single lab, two orthogonal methods\",\n      \"pmids\": [\"26694610\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"FcγRIIB mediates anti-CD28 superagonist TGN1412 activity: FcγRIIB expression on monocytes (which is logarithmically upregulated during high-density preculture) is necessary and sufficient for TGN1412-mediated T cell proliferation, acting by crosslinking the antibody.\",\n      \"method\": \"High-density vs low-density preculture PBMC assays; FcγRIIB expression measurement by flow cytometry; reconstitution experiments mixing FcγRIIB+ monocytes with LD T cells; B cell FcγRIIB functional assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reconstitution experiment with defined cell populations establishes FcγRIIB on monocytes as required effector; single lab, multiple cell manipulation approaches\",\n      \"pmids\": [\"25395427\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"FcγRIIB mediates antigen-independent inhibition of human B cells (naïve B cells, memory B cells, and plasma cells) through Btk and p38 MAPK; FcγRIIB crosslinking eliminates antibody-secreting plasma cells and blocks naïve B cell proliferation without affecting memory B cell activation.\",\n      \"method\": \"FcγRIIB crosslinking on sorted human B cell subsets; Btk and p38 MAPK inhibitor assays; proliferation and differentiation assays\",\n      \"journal\": \"Journal of biomedical science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological pathway dissection (Btk and p38 inhibitors) in primary human cells; single lab; multiple B cell subsets tested\",\n      \"pmids\": [\"26475492\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FcγRIIB activation by hyposialylated IgG in endothelium impairs endothelial cell insulin transcytosis, reducing insulin delivery to skeletal muscle and causing obesity-induced insulin resistance; endothelium-specific FcγRIIB deletion protects mice from HFD-induced insulin resistance; IgG from T2DM patients is hyposialylated and causes insulin resistance via FcγRIIB.\",\n      \"method\": \"Global and endothelium-specific FcγRIIB KO mice; HFD model; IgG transfer into IgG-deficient mice; in vitro endothelial insulin transcytosis assay; IgG sialylation analysis\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific KO, adoptive IgG transfer, in vitro transcytosis mechanism, and human patient IgG validation provide convergent evidence; multiple orthogonal approaches\",\n      \"pmids\": [\"29202472\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"IVIG attenuates post-ICH mast cell activation via the FcγRIIB/SHIP1/PIP3 pathway: FcγRIIB engagement activates SHIP1, hydrolyzing PIP3 and inhibiting calcium mobilization and mast cell degranulation; in vivo siRNA knockdown of SHIP1 abolishes IVIG's protective effects.\",\n      \"method\": \"ICH collagenase mouse model; siRNA-mediated in vivo SHIP1 knockdown; mast cell degranulation assays; brain edema and neurological function assessment\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo siRNA epistasis confirms SHIP1 as effector; single lab; functional neurological readouts validate pathway\",\n      \"pmids\": [\"29138419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The I232T polymorphism in the transmembrane domain of FcγRIIB tilts the TM domain, bending the ectodomain toward the plasma membrane to allosterically impede ligand (IgG1/IgG2/IgG3) binding, reducing in situ 2D binding affinities and association rates by 3–4 fold.\",\n      \"method\": \"Single-cell FRET assay; molecular dynamics simulations; in situ 2D binding kinetics measurements\",\n      \"journal\": \"eLife (PMID 31343409, published 2019)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — FRET structural assay combined with MD simulation and quantitative binding kinetics; mechanistic link from TM tilt to ectodomain conformation to ligand affinity established in one study\",\n      \"pmids\": [\"31343409\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"FcγRIIB expressed in neurons acts as a receptor for α-synuclein fibrils and mediates cell-to-cell transmission (prion-like propagation) of α-syn; SHP-1 and SHP-2 are activated downstream of FcγRIIB by α-syn fibrils and are required for α-syn transmission and Lewy body-like inclusion formation.\",\n      \"method\": \"Co-culture neuronal transmission assay; FcγRIIB-blocking/KO experiments; SHP-1/SHP-2 phosphorylation assays; Lewy body-like inclusion quantification\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — receptor identity established by blockade/KO; downstream SHP-1/2 activation measured; single lab; co-culture system demonstrates transmission\",\n      \"pmids\": [\"29298416\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FcγRIIB differentially regulates B cell tolerance checkpoints: reduced FcγRIIB enhances deletion/anergy of autoreactive immature B cells (pre-immune checkpoint) but promotes autoreactive B cell expansion in germinal centers and autoantibody production (post-immune checkpoint), demonstrating opposing effects at distinct developmental stages.\",\n      \"method\": \"FcγRIIB-deficient and transgenic mice; B cell tolerance assays with defined autoreactive BCR models; germinal center analysis; autoantibody measurement\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic models at multiple B cell stages with defined autoreactive BCR transgenes; opposing effects at two checkpoints validated with multiple readouts\",\n      \"pmids\": [\"31036800\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Follicular dendritic cells (FDCs) upregulate FcγRIIB during germinal center (GC) formation; FDC-specific FcγRIIB deficiency leads to aberrant GC B cell selection, increased GC diversity (persistence of IgM+ clones, fewer IgH mutations), indicating FDCs modulate GC B cell selection via FcγRIIB.\",\n      \"method\": \"Stromal-specific FcγRIIB KO mice; AidCreERT2-confetti clonal tracking; GC B cell frequency and mutation analysis; autoreactive and foreign antigen immunization models\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific genetic KO with clonal tracking system; multiple antigen models; mechanistic dissection of FDC role in GC selection\",\n      \"pmids\": [\"31775042\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"FcγRIIB is expressed on a subset of effector CD8+ T cells following activation; cell-intrinsic FcγRIIB signaling induces caspase-3/7-mediated apoptosis in CD8+ T cells upon engagement by its functional ligand fibrinogen-like protein 2 (Fgl2), thereby limiting CD8+ T cell accumulation; IgG is not required for this pathway.\",\n      \"method\": \"Fcgr2b cell-intrinsic KO CD8+ T cells; graft rejection and tumor models; caspase-3/7 apoptosis assay; Fgl2 binding assay; IgG-deficient mouse controls\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-intrinsic genetic deletion with adoptive transfer; Fgl2 identified as functional ligand; caspase-3/7 mechanism defined; multiple disease models; replicated across labs implied by IgG KO control\",\n      \"pmids\": [\"31940267\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FcγRIIB inhibits antibody-mediated target cell depletion through competition with activating FcγRs for antibody Fc binding, independently of ITIM signaling; ITIM-null FcγRIIB expressed on target or effector cells still impairs mAb-mediated depletion through three therapeutically relevant surface receptors (CD20, CD25, OX40).\",\n      \"method\": \"Human FcγRIIB transgenic models with ITIM-intact vs ITIM-mutant receptors on targets or effectors; in vivo tumor depletion assays; in vitro ADCP assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ITIM-null knock-in genetic models definitively separate competition mechanism from ITIM signaling; multiple targets tested; both in vitro and in vivo validation\",\n      \"pmids\": [\"35858562\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FcγRIIB expression in marginal zone (MZ) B cells is highest among B cell subsets; high FcγRIIB expression limits MZ B cell activation, ERK phosphorylation, and calcium flux; B cell-conditional Fcgr2b KO leads to spontaneous IgG3 autoantibody increase driven by extrafollicular MZ B cell responses.\",\n      \"method\": \"Fcgr2b conditional KO mice; MZ B cell subset analysis by flow cytometry; ERK phosphorylation and calcium flux assays; Notch2/Fcgr2b double KO to eliminate MZ B cells\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with double-KO epistasis identifies MZ B cell as key cellular locus; multiple signaling readouts; human SLE validation\",\n      \"pmids\": [\"35819855\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"FcγRIIB on CD8+ T cells limits responsiveness to PD-1 checkpoint inhibition in a cell-intrinsic, Fc-dependent manner: FcγRIIBpos CD8+ T cells show reduced response to PD-1 and CTLA-4 checkpoint inhibitors; conditional Fcgr2b deletion on tumor-specific CD8+ T cells improves checkpoint blockade response; Fc-devoid anti-PD-1 F(ab) restores FcγRIIBpos T cell proliferation.\",\n      \"method\": \"Conditional Fcgr2b KO on CD8+ T cells; Fc-devoid F(ab) anti-PD-1 comparison; in vivo B16, LLC, and MC38 tumor models; human melanoma patient FcγRIIBpos CD8+ T cell analysis\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional genetic deletion, Fc-null antibody comparison, multiple tumor models, and human patient validation define a cell-intrinsic Fc-dependent mechanism\",\n      \"pmids\": [\"37611081\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CRP activates Smad3 via the CD32b–ERK/p38 MAP kinase crosstalk pathway (within 15 min, directly) and through TGF-β1 (at 24 h, indirectly); CRP also activates mTOR signaling via a Smad3-dependent mechanism (Smad3 physically binds mTOR); CD32b neutralizing antibody and Smad3 inhibitor abolish CRP-induced mTOR activation and renal fibrosis.\",\n      \"method\": \"CRPtg-db/db mouse model; in vitro renal tubular epithelial cell CRP stimulation; Smad3 inhibitor; CD32b neutralizing antibody; co-immunoprecipitation of Smad3 with mTOR; rapamycin treatment\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP of Smad3–mTOR complex; multiple inhibitors; in vivo and in vitro concordance; single lab\",\n      \"pmids\": [\"27221338\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FcγRIIB (FCGR2B/CD32B) is the sole inhibitory IgG Fc receptor; upon co-ligation with activating receptors (BCR, FcεRI, Kit, activating FcγRs), its ITIM is phosphorylated by Src-family kinases, recruiting SHIP to hydrolyze PIP3 and suppress Akt/calcium signaling, while its transmembrane domain (disrupted by the I232T/I187T SLE-risk polymorphism) allosterically controls ligand binding affinity; FcγRIIB also crosslinks with dectin-1 in a galactosylated-IgG–dependent manner to suppress complement signaling, acts as a neuronal receptor for Aβ oligomers and α-synuclein fibrils triggering ER stress/SHP-1/2, mediates CRP inhibition of eNOS via PP2A in endothelium, induces apoptosis in plasma cells and CD8+ T cells (via Fgl2–caspase-3/7), limits CD8+ T cell responses to checkpoint inhibitors in an Fc-dependent cell-intrinsic manner, and is subject to ubiquitin-mediated downregulation by the E3 ligase MARCH3 upon TLR4 activation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"FcγRIIB (CD32B) is the inhibitory IgG Fc receptor that sets thresholds for immune-cell activation and tolerance, principally by co-clustering with activating immunoreceptors and dampening their downstream signaling [#0, #20]. Upon co-ligation with the B-cell antigen receptor, Kit, or other activating receptors, its phosphorylated ITIM recruits the inositol 5'-phosphatase SHIP rather than SHP-1; SHIP hydrolyzes PIP3, blocking Akt activation, calcium influx, and CD19 phosphorylation despite intact PI3K activity [#0, #1, #2]. This SHIP-dependent module suppresses BCR-driven BLyS survival signaling, mast-cell proliferation and degranulation, and antigen-independent human B-cell responses through Btk and p38 MAPK [#2, #10, #15, #17]. The receptor's transmembrane domain independently tunes function: the SLE-associated I232T polymorphism tilts the TM helix, bending the ectodomain toward the membrane to allosterically reduce IgG binding affinity, while also altering ITIM-independent inhibition of BCR signaling [#4, #18]. FcγRIIB output is governed at the expression level through promoter polymorphisms that alter transcription-factor binding and receptor abundance [#3, #5], and post-translationally by TLR4-induced MARCH3-mediated ubiquitination and downregulation [#13]. Beyond canonical inhibition, FcγRIIB acts as a pro-apoptotic and signaling receptor in multiple contexts: crosslinking eliminates bone-marrow plasma cells, plasmablasts, and myeloma cells, and engagement of the functional ligand FGL2 induces caspase-3/7 apoptosis in B cells and effector CD8+ T cells independently of IgG [#7, #9, #22]. It restrains autoreactive B-cell selection within germinal centers, including on follicular dendritic cells and marginal-zone B cells [#20, #21, #24], limits CD8+ T-cell responsiveness to PD-1/CTLA-4 checkpoint blockade in a cell-intrinsic Fc-dependent manner [#25], and impairs therapeutic antibody-mediated target depletion by competing with activating FcγRs for Fc binding even without ITIM signaling [#23]. FcγRIIB additionally functions outside the immune system as an endothelial and neuronal receptor: it mediates CRP-driven PP2A inhibition of eNOS and hyposialylated-IgG impairment of insulin transcytosis driving insulin resistance [#6, #16], crosslinks with dectin-1 in a galactosylated-IgG-dependent manner to suppress complement signaling [#11], and binds Aβ oligomers and α-synuclein fibrils on neurons to trigger ER stress, caspase-12, and SHP-1/SHP-2 activation [#12, #19].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Resolved which phosphatase executes FcγRIIB inhibition, establishing SHIP rather than SHP-1 as the effector recruited to the phosphorylated receptor in B cells.\",\n      \"evidence\": \"Co-IP of SHIP with FcγRIIB and calcium assays in SHP-1-deficient (motheaten) vs normal B cell lines\",\n      \"pmids\": [\"9242674\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define which kinase phosphorylates the ITIM\", \"Did not establish the lipid substrate consumed by SHIP\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Defined the biochemical mechanism downstream of SHIP, showing it consumes PIP3 to block Akt despite normal PI3K activity.\",\n      \"evidence\": \"PIP3 measurement and Akt kinase assays in A20 B cells with catalytic-dead SHIP and SHIP-null comparisons\",\n      \"pmids\": [\"10224144\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address SHIP-independent inhibitory branches\", \"Restricted to B-cell context\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Extended the inhibitory module beyond the BCR, showing FcγRIIB-SHIP suppresses Kit-driven mast cell proliferation and cell-cycle entry.\",\n      \"evidence\": \"Co-aggregation, cell cycle analysis, SHIP-null cells, and SHIP catalytic-domain chimeric receptors in mast cells\",\n      \"pmids\": [\"12217398\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the residual SHIP-independent inhibition unresolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Linked receptor abundance to autoimmunity, showing a promoter polymorphism abolishing AP-4 binding lowers FcγRIIB in germinal-center B cells and raises IgG responses.\",\n      \"evidence\": \"Luciferase reporters, EMSA, and NZB-allele congenic mice\",\n      \"pmids\": [\"12370366\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Murine allele; human relevance addressed separately\", \"Did not test causal link to overt autoantibody disease\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Demonstrated that the transmembrane I232T/I187T polymorphism alters signaling independently of the ITIM, implicating the TM domain in receptor function.\",\n      \"evidence\": \"Reconstitution of allelic and ITIM-truncated constructs in FcγRIIB-negative B cells with CD19 phosphorylation and calcium assays\",\n      \"pmids\": [\"14613290\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the TM effect not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identified a human promoter haplotype that raises FcγRIIB expression and associates with SLE susceptibility.\",\n      \"evidence\": \"Luciferase reporters in B and myeloid lines plus case-control genetics in 600 Caucasians\",\n      \"pmids\": [\"15153543\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single functional reporter method\", \"Transcription factors mediating the difference not identified\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Established a non-immune endothelial function, showing CRP signals via FcγRIIB to activate PP2A and blunt eNOS.\",\n      \"evidence\": \"PP2A siRNA, heterologous expression, and FcγRIIB KO mouse vascular conductance assays\",\n      \"pmids\": [\"16269657\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct CRP-FcγRIIB binding affinity not quantified\", \"Coupling between receptor and PP2A activation undefined\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Revealed a pro-apoptotic role, showing FcγRIIB crosslinking eliminates plasma cells and that lupus plasma cells escape by losing the receptor.\",\n      \"evidence\": \"Crosslinking apoptosis assays in mouse and human plasma cells/myeloma and lupus-prone mouse comparison\",\n      \"pmids\": [\"17322888\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Apoptotic signaling pathway not delineated\", \"Endogenous ligand triggering apoptosis not identified here\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified FGL2 as a direct FcγRIIB ligand mediating immunosuppression and DC tolerance.\",\n      \"evidence\": \"SPR binding, FcγRIIB-null cells, and skin allograft survival in KO mice\",\n      \"pmids\": [\"18991288\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Binding interface on receptor and ligand not mapped\", \"Downstream apoptotic effectors not defined here\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Dissected cell-autonomous roles, showing B-cell FcγRIIB controls autoimmunity while macrophage FcγRIIB affects infection outcome.\",\n      \"evidence\": \"Cell-type-specific transgenic overexpression with arthritis, SLE, and S. pneumoniae models\",\n      \"pmids\": [\"18362174\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of macrophage-specific infection susceptibility unresolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Connected FcγRIIB inhibition to B-cell survival, showing it dampens BLyS-receptor upregulation and downstream survival signals via SHIP1.\",\n      \"evidence\": \"B cell co-aggregation with SHIP1-deficient comparison and BLyS signaling readouts\",\n      \"pmids\": [\"18791164\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Mechanism linking SHIP1 to BLyS receptor expression indirect\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Uncovered a glycan-dependent partnership with dectin-1 that suppresses complement-driven inflammation.\",\n      \"evidence\": \"Reciprocal Co-IP, SHIP/Syk phosphorylation, glycan-manipulated IgG1, and in vivo disease models\",\n      \"pmids\": [\"22922409\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of the FcγRIIB-dectin-1 complex unknown\", \"Structural basis of galactose dependency undefined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Established FcγRIIB as a neuronal Aβ-oligomer receptor mediating Alzheimer's neurotoxicity.\",\n      \"evidence\": \"Aβ-FcγRIIB binding, KO neuron resistance, ER stress/caspase-12 assays, and LTP/memory rescue in AD mice\",\n      \"pmids\": [\"23921129\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling between receptor and ER stress not fully mapped\", \"Relationship to ITIM/SHIP module in neurons unclear\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified MARCH3 as the E3 ligase downregulating FcγRIIB after TLR4 activation, defining post-translational regulation.\",\n      \"evidence\": \"Ubiquitination assays and MARCH3 siRNA in LPS-treated monocytes\",\n      \"pmids\": [\"26694610\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; ubiquitination site not mapped\", \"Direct MARCH3-FcγRIIB interaction not shown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showed FcγRIIB on monocytes is necessary and sufficient to crosslink the anti-CD28 superagonist TGN1412 and drive T-cell proliferation.\",\n      \"evidence\": \"Density-dependent FcγRIIB upregulation and monocyte/T-cell reconstitution in PBMC\",\n      \"pmids\": [\"25395427\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Mechanism of density-driven upregulation not defined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined antigen-independent inhibition of human B-cell subsets through Btk and p38 MAPK with subset-selective effects.\",\n      \"evidence\": \"Crosslinking on sorted human B cell subsets with Btk and p38 inhibitor dissection\",\n      \"pmids\": [\"26475492\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Relationship between Btk/p38 branch and SHIP branch unresolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Linked CRP-FcγRIIB signaling to fibrosis via ERK/p38-Smad3-mTOR crosstalk.\",\n      \"evidence\": \"CRPtg-db/db mice, CD32b neutralizing antibody, Smad3 inhibitor, and Smad3-mTOR Co-IP\",\n      \"pmids\": [\"27221338\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Direct receptor-to-Smad3 coupling not biochemically defined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Extended endothelial signaling to metabolism, showing hyposialylated IgG-FcγRIIB impairs insulin transcytosis and causes insulin resistance.\",\n      \"evidence\": \"Endothelium-specific KO mice, HFD, IgG transfer, in vitro transcytosis, and T2DM patient IgG\",\n      \"pmids\": [\"29202472\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Intracellular signaling controlling transcytosis not delineated\", \"Glycan recognition mechanism on receptor unclear\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Confirmed in vivo that the FcγRIIB/SHIP1/PIP3 axis controls mast cell degranulation, mediating IVIG therapeutic benefit after hemorrhage.\",\n      \"evidence\": \"ICH mouse model with in vivo SHIP1 siRNA knockdown and degranulation/neurological readouts\",\n      \"pmids\": [\"29138419\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"IgG species engaging FcγRIIB in vivo not defined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Provided a structural mechanism for the I232T polymorphism, showing TM tilt bends the ectodomain to reduce IgG binding affinity.\",\n      \"evidence\": \"Single-cell FRET, molecular dynamics, and in situ 2D binding kinetics\",\n      \"pmids\": [\"31343409\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Link between altered affinity and disease risk in vivo not demonstrated here\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified FcγRIIB as a neuronal α-synuclein fibril receptor driving prion-like transmission via SHP-1/SHP-2.\",\n      \"evidence\": \"Co-culture transmission assay with FcγRIIB blockade/KO and SHP-1/2 phosphorylation\",\n      \"pmids\": [\"29298416\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Direct fibril-receptor binding affinity not quantified\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstrated stage-dependent, opposing roles of FcγRIIB at pre- and post-immune B-cell tolerance checkpoints.\",\n      \"evidence\": \"Deficient and transgenic mice with defined autoreactive BCR models and germinal-center analysis\",\n      \"pmids\": [\"31036800\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of opposing effects at the two checkpoints unresolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed FcγRIIB on follicular dendritic cells shapes germinal-center B-cell selection and clonal diversity.\",\n      \"evidence\": \"Stromal-specific KO with confetti clonal tracking and mutation analysis\",\n      \"pmids\": [\"31775042\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling consequence of FDC FcγRIIB engagement not defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Established a cell-intrinsic apoptotic pathway in CD8+ T cells, with Fgl2 triggering caspase-3/7 to limit T-cell accumulation independently of IgG.\",\n      \"evidence\": \"Cell-intrinsic Fcgr2b KO CD8+ T cells, Fgl2 binding, caspase assays, and IgG-deficient controls in graft/tumor models\",\n      \"pmids\": [\"31940267\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling between FcγRIIB and caspase activation in T cells not mapped\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Separated an ITIM-independent competition mechanism, showing FcγRIIB blocks therapeutic antibody depletion by sequestering Fc from activating FcγRs.\",\n      \"evidence\": \"ITIM-null knock-in transgenic models with in vivo depletion and ADCP assays across CD20, CD25, OX40\",\n      \"pmids\": [\"35858562\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution of competition vs ITIM signaling in disease unclear\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identified marginal-zone B cells as a key cellular locus where high FcγRIIB restrains extrafollicular autoantibody responses.\",\n      \"evidence\": \"Conditional KO with Notch2 double-KO epistasis, signaling readouts, and human SLE validation\",\n      \"pmids\": [\"35819855\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why MZ B cells express the highest FcγRIIB not explained\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed FcγRIIB on CD8+ T cells limits checkpoint-inhibitor responsiveness in a cell-intrinsic, Fc-dependent manner.\",\n      \"evidence\": \"Conditional Fcgr2b KO, Fc-devoid anti-PD-1 F(ab), multiple tumor models, and human melanoma patient analysis\",\n      \"pmids\": [\"37611081\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the Fc-dependent effect uses ITIM/SHIP or competition not resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the divergent FcγRIIB outputs—SHIP-dependent inhibition, ITIM-independent Fc competition, FGL2-driven apoptosis, and neuronal aggregate sensing—are mechanistically unified or selected in different cell types remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model linking ligand identity to choice of downstream effector\", \"Switch between inhibitory and pro-apoptotic signaling undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": [12, 19]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1, 2, 23]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 9, 22]},\n      {\"term_id\": \"GO:0038024\", \"supporting_discovery_ids\": [23]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 4, 18, 6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 7, 20, 22, 25]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 2, 6, 11]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [7, 22]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"SHIP\", \"FGL2\", \"CLEC7A\", \"MARCH3\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}